Roche Holding AG (0QOK.L)
| Previous close | 327.18 |
| Open | 324.60 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 324.60 - 327.95 |
| 52-week range | 246.30 - 335.60 |
| Volume | |
| Avg. volume | 389,242 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.
- Yahoo Finance Video
How Roche aims to change the 'standard of care'
Speaking at the JPMorgan Healthcare Conference, Roche Pharmaceuticals (RHHBY) CEO Teresa Graham discusses the company's innovation focus and outlook with Yahoo Finance's Anjalee Khemlani. Graham says Roche has "defined itself as a company that follows innovation" across health care sectors. Currently, they see huge potential in the obesity drug space as analysts forecast the weight loss market reaching $100 billion within years. However, Roche hopes to expand cretinism beyond obesity into neurological disease applications. On dealmaking, Graham notes Roche pursues "groundbreaking science" that can "materially change the standard of care" for high unmet-need diseases. She stresses they remain open across therapeutic areas to back advances that drive health forward. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith
- Yahoo Finance Video
How GLP-1 weight loss drugs dominated 2023
Coming in at Number 5 on Yahoo Finance's countdown of the top stories of 2023 is the breakout success of GLP-1 weight loss drugs. This new class of diabetes and obesity medications, led by Novo Nordisk's Wegovy (NVO) and Eli Lilly's Mounjaro (LLY), have shown dramatic weight loss results of 15-20% in clinical trials. Yahoo Finance Health Reporter Anjalee Khemlani provides an in-depth analysis of the frenzy over these injectable treatments and what's driving the demand. As major pharmaceutical companies like Pfizer (PFE) and Roche (ROG.SW) prepare to enter the market in 2024, she explores what lies ahead. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
